US EditionNovo Nordisk Weakens Again on Interim Results Readout
6 Articles
6 Articles
The Danish pharmaceutical company Novo Nordisk was seen as a source of hope in the fight against obesity – and became Europe's most valuable share. But the euphoria has vanished, the price has collapsed. Is there now a second chance for those who once missed the legendary stock market rise?
The company loses more than half of its value since the beginning of the year. The new CEO will assume the position tomorrow
Ozempic Maker Novo Nordisk Posts Strong Results But Competition Weighs
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States.
Slowdown in GLP-1 Sales Sends Novo Nordisk Stock Lower - Wall Street Pit
Novo Nordisk (NVO) stock fell over 2% to $46.19 in pre-market trading after a 3.26% drop to $47.22, driven by a Q2 earnings miss with $11.95 billion in revenue and $5.96 EPS, slightly below Wall Street’s expectations of $11.97 billion and $6.06. The company faces challenges from unauthorized semaglutide copycats,…
Danish pharmaceutical giant Novo Nordisk reports slightly below analysts' expectations. The company says it will present measures, but analysts say it still has no answer on how it will address challenges.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
